According to Zacks, “Burning Rock Biotech Limited focuses on the application of next generation sequencing technology in the field of precision oncology. Its business consists of NGS-based therapy selection testing for late-stage cancer patients as well as NGS-based cancer early detection. Burning Rock Biotech Limited is based in GUANGZHOU, China. “
BNR traded down $0.34 during midday trading on Tuesday, hitting $2.66. 275,555 shares of the company traded hands, compared to its average volume of 302,140. The company’s 50-day moving average is $6.94 and its 200 day moving average is $9.17. Burning Rock Biotech has a 52 week low of $2.63 and a 52 week high of $34.71. The firm has a market capitalization of $279.59 million, a PE ratio of -2.25 and a beta of -0.33.
Several hedge funds have recently bought and sold shares of BNR. Jane Street Group LLC bought a new stake in Burning Rock Biotech in the first quarter worth $97,000. State Street Corp lifted its position in shares of Burning Rock Biotech by 12.9% during the first quarter. State Street Corp now owns 196,590 shares of the company’s stock worth $1,826,000 after purchasing an additional 22,457 shares during the last quarter. Invesco Ltd. increased its stake in shares of Burning Rock Biotech by 60.3% during the first quarter. Invesco Ltd. now owns 60,609 shares of the company’s stock valued at $563,000 after buying an additional 22,805 shares during the period. Vanguard Group Inc. increased its stake in shares of Burning Rock Biotech by 2.6% during the first quarter. Vanguard Group Inc. now owns 1,053,368 shares of the company’s stock valued at $9,786,000 after buying an additional 26,289 shares during the period. Finally, Kynam Capital Management LP increased its stake in shares of Burning Rock Biotech by 102.1% during the first quarter. Kynam Capital Management LP now owns 773,114 shares of the company’s stock valued at $7,182,000 after buying an additional 390,650 shares during the period. 45.05% of the stock is owned by hedge funds and other institutional investors.
Burning Rock Biotech Company Profile (Get Rating)
Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
- Get a free copy of the StockNews.com research report on Burning Rock Biotech (BNR)
- Zoom Video Communications Is Primed To Launch Higher
- Institutions Buy The Dip In Petco Health and Wellness Company
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Burning Rock Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Burning Rock Biotech and related companies with MarketBeat.com's FREE daily email newsletter.